Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial.

@article{Margreiter2008AlemtuzumabA,
  title={Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial.},
  author={Raimund Margreiter and J{\"u}rgen Klempnauer and Peter Neuhaus and Ferdinand Muehlbacher and Claudia B{\"o}sm{\"u}ller and Roy Yorke Calne},
  journal={American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons},
  year={2008},
  volume={8 7},
  pages={1480-5}
}
The lymphocyte-depleting antibody alemtuzumab was evaluated in a prospective randomized multicenter trial in deceased donor kidney transplantation. The 65 patients in the study group received induction with alemtuzumab followed by delayed tacrolimus monotherapy, while the 66 patients in the control group were started on tacrolimus in combination with mycophenolate mofetil and steroids. Tacrolimus levels of 8-12 ng/mL for the first 6 months and 5-8 ng/mL thereafter were aimed for in both groups… CONTINUE READING

From This Paper

Topics from this paper.
40 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 40 extracted citations

Similar Papers

Loading similar papers…